NCT07170111Not yet recruiting
Predictors of GON Blockade Success in Migraine
Predictive Factors for the Success of Greater Occipital Nerve Block in Migraine: A Multicenter Prospective Study
Source: ClinicalTrials.gov · Last updated 12 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This multicenter, prospective cohort study aims to identify clinical and demographic predictors that influence the success of greater occipital nerve (GON) block in patients with migraine. Patients will be evaluated at baseline, on each injection day, and at one- and three-month follow-ups. Study parameters include demographics, migraine type and duration, comorbidities, headache characteristics, treatment history, and validated outcome measures such as the Numeric Rating Scale (NRS), Headache Impact Test-6 (HIT-6), and Global Rating of Change (GRoC). The goal is to establish predictive factors of treatment success in order to optimize patient selection and contribute robust multicenter evidence to individualized migraine management
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 460 (estimated)
- First submitted
- 22 Aug 2025
- Start date
- 15 Sept 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Başakşehir Çam & Sakura City Hospital
- Diseases
- Migraine
- NCT number
- NCT07170111
What you commit to
- Study type: Interventional
- Planned participants: 460
- From 15 Sept 2025 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Coagulopathy or anticoagulant therapy
- Receipt of interventional treatment (e.g., Botox, acupuncture, neural therapy, nerve blocks) within the last 3 months
- Use of steroids or immunosuppressive therapy
- Start of a new preventive therapy within the last 3 months
Other illness
- Presence of malignancy
- Local infection, open wound, or history of surgery at the injection site preventing the procedure
- History of severe neurological or psychiatric disorders
- Known hypersensitivity or allergy to bupivacaine
Other
- Pregnancy or breastfeeding
- Inability to comply with keeping a headache diary
Who the study is looking for
- Diagnosis of migraine for at least 6 months, according to ICHD-3 criteria
- Age between 18 and 65 years
- Inadequate response to preventive therapy used regularly for at least 3 months
- Planned treatment with greater occipital nerve block (GONB) and provision of signed informed consent
- Receiving GONB treatment for the first time
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Başakşehir Çam and Sakura City Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.